Skip to content

Clinical, genomic, and spatial transcriptomic features of pancreatic adenosquamous carcinoma support subtype-specific therapeutic strategies.

Aug 2026 · Clinical Cancer Research · pp. OF1-OF15 · 0 citations
Medicine

TL;DR

Despite shared genomic drivers with PDAC, ASQ exhibits transcriptionally distinct features with spatially organized tumor and immune heterogeneity, supporting the need for subtype-specific therapeutic strategies.

Abstract

Purpose

Pancreatic adenosquamous carcinoma (ASQ) is a rare variant with poorly defined clinical and molecular features compared to conventional pancreatic ductal adenocarcinoma (PDAC). This study aimed to characterize the clinical outcomes, genomic landscape, and spatial transcriptomic architecture of ASQ. EXPERIMENTAL

Design

We retrospectively evaluated clinicopathologic features, treatment patterns, and survival of ASQ patients treated at Johns Hopkins from 2013-2023 (n=178). Genomic landscapes of ASQ (n=244) versus PDAC (n=29,021) were compared using the FoundationCore database. Surgically resected ASQ tumors (n=11 from 8 patients) were analyzed using Visium spatial transcriptomics with a comparator PDAC dataset (n=4).

Results

ASQ patients had poor outcomes in both resected and advanced disease. FoundationCore analysis revealed similar KRAS mutation frequency, higher MTAP loss, and enrichment of low-frequency immune biomarkers (MSI-high, PD-L1+, TMB ³10 muts/Mb) in ASQ compared with PDAC. Spatial transcriptomics revealed broadly similar immune cell proportions across subtypes, with higher regulatory T-cell abundance observed in ASQ in the context of sparse detection in PDAC. Differences in spatial co-localization patterns of immune populations were observed between ASQ and PDAC, while distance analyses within ASQ showed immune infiltrates closest to squamous regions and farthest from glandular regions. Furthermore, ASQ showed increased squamous/basal lineage expression compared with PDAC, with intratumoral squamous regions enriched for epithelial-mesenchymal transition, apical junction, inflammatory, and stress response pathways relative to the glandular niche.

Conclusions

Despite shared genomic drivers with PDAC, ASQ exhibits transcriptionally distinct features with spatially organized tumor and immune heterogeneity, supporting the need for subtype-specific therapeutic strategies.

View source

Similar papers

Sep 2026

Abstract A034: Spatial multi-omics defines cancer-like precursor lesions in human pancreas

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of pancreatic cancer classically driven by oncogenic KRAS mutations. It is thought to arise from precursor lesions including intraductal papillary mucinous neoplasia (IPMN) and pancreatic intraepithelial neoplasia (PanIN). We have recently reported that Pa...

J. Okoye, Rosina Carr, Carlos E. Espinoza et al. · 0 citations
Aug 2026

Clinicopathological Profiles and Prognosis of Postoperative HER2-Mutant Non-Small Cell Lung Cancer: A Real-World Analysis.

Her2-mutant NSCLC constitutes a distinct subtype characterized by unique clinicopathological and molecular features and for postoperative patients presenting with advanced disease or an increased burden of high-risk recurrence factors, more aggressive therapeutic strategies should be considered.

Guang-Jian Yang, Linyan Tian, Xiao-Yong Tang et al. · 0 citations
Sep 2026

Abstract PR015: Clonal Heterogeneity in Human Pancreatic Ductal Adenocarcinoma and Its Impact on Tumor Progression

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by profound desmoplasia and cellular heterogeneity, which cannot be fully resolved using traditional bulk sequencing approaches. To understand how this heterogeneity contributes to PDAC biology, we analyzed a large cohort of primary tumors...

Despoina Kalfakakou, Sungsik Kim, Li-Dong Wang et al. · 0 citations
Open access Aug 2026

Clinicopathologic and prognostic value of HER2 alterations in non-small cell lung cancer

Human epidermal growth factor receptor 2 ( HER2 ) alterations represent emerging therapeutic targets in non-small cell lung cancer (NSCLC). However, the clinicopathological and prognostic values of HER2 mutations, amplification, and over expression remain poorly defined, leading to uncertainty in their prog...

Yicong Lin, Qian-Qian Xue, Bingxia Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.